The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects

British Journal of Clinical Pharmacology

Volumn 69, Issue 1, 2010, Pages 23-26

  Stavros, Fiona ^a   Kramer, William G ^b   Wilkins, Martin R ^c  

^a TEXAS BIOTECHNOLOGY CORPORATION   (United States)

^b Kramer Consulting LLC   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Blood pressure; N desmethylsildenafil; Pharmacokinetics; Sildenafil; Sitaxentan

Indexed keywords

PLACEBO; SILDENAFIL; SITAXSENTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

ADULT; AREA UNDER CURVE; BLOOD PRESSURE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PIPERAZINES; PURINES; RECEPTORS, ENDOTHELIN; SULFONES; THIOPHENES; VASODILATOR AGENTS; YOUNG ADULT;

EID: 72949114651     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03541.x     Document Type: Article

References (6)

1. Hoeper MM, Dinh-Xuan AT. Combination therapy for pulmonary arterial hypertension: still more questions than answers. Eur Respir J 2004 24 : 339 340.
2. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, 2001. Available at http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf (last accessed 17 June 2009).
3. Stavros FL, Kramer WG, Ogilvie BW, Parkinson A. The victim potential of sitaxentan: metabolism by human CYP enzymes. European Respiratory Society 2008 abstract 2667.
4. Pfizer. Revatio (sildenafil citrate) Prescribing Information. 2008.
5. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005 60 : 107 112.
6. Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008 64 : 43 50.